MedTrace Logo

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

NCT02437279 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-15

No results posted yet for this study

Summary

This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.

Conditions

  • Stage III Skin Melanoma

Interventions

PROCEDURE

Surgery of the tumor

DRUG

Infusion with ipilimumab 3 mg/kg q3wks

DRUG

Infusion with nivolumab 1 mg/kg q3wks

Sponsors & Collaborators

Principal Investigators

  • Christian Blank, MD PhD · The Netherlands Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-24
Primary Completion
2018-06-28
Completion
2025-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02437279 on ClinicalTrials.gov